About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Gluten-Free Pills: FDA Issues Guidance For Labeling

by Julia Samuel on December 13, 2017 at 3:49 PM
Font : A-A+

Gluten-Free Pills: FDA Issues Guidance For Labeling

FDA agency is pushing drugmakers to clearly label that medications taken orally don't have ingredients from grains that include gluten like wheat, barley or rye.

Currently there are no drugs marketed in the U.S. that contain gluten in a quantity that would exceed the amount in a gluten-free food product, the FDA said. The new rules are an attempt to reduce uncertainty for people with gluten sensitivities or diseases aggravated by ingesting gluten.

Advertisement


"Transparency about what we're putting into our bodies matters to all of us," FDA Commissioner Scott Gottlieb said in a statement. "We have made great strides in enhancing transparency about gluten in food labeling, but because there has been uncertainty about gluten in certain drug products, some patients may be avoiding medications that would otherwise offer a health benefit."

Roughly one in 100 people globally are estimated to have celiac disease, according to the Celiac Disease Foundation, an autoimmune disorder where the consumption of gluten can lead to damage of the small intestine.
Advertisement

How Does FDA Define 'Gluten-Free'?

In addition to limiting the unavoidable presence of gluten to less than 20 ppm, FDA now allows manufacturers to label a food "gluten-free" if the food does not contain any of the following:
  • an ingredient that is any type of wheat, rye, barley, or crossbreeds of these grains
  • an ingredient derived from these grains and that has not been processed to remove gluten
  • an ingredient derived from these grains and that has been processed to remove gluten, if it results in the food containing 20 or more parts per million (ppm) gluten
Under the final rule, a food label that bears the claim "gluten-free," as well as the claims "free of gluten," "without gluten," and "no gluten," but fails to meet the requirements of the rule is considered misbranded and subject to regulatory action by FDA.

Source: Medindia
Advertisement

Advertisement
Advertisement

Recommended Reading

Latest Drug News

 FDA Issues Warning About Compounded Diabetes Drug Semaglutide Products
The FDA advises consumers not to use compounded medications as an alternative to known diabetic and weight reduction medications Ozempic, Rybelsus, and Wegovy.
 Parkinson's Unmet Needs Creates Path for New Entrants into the Market
Addressing the unmet needs of Parkinson's Disease by providing disease-modifying therapies could bring about a major shift in the way that patients are treated.
How Microrobots Could Help Treat Bladder Diseases?
Microrobots could swirl through a person's blood stream, search for targeted areas to treat for various ailments.
How Can Multivitamin Supplements Slow Cognitive Aging?
Supplementation with multivitamins is an inexpensive way for older adults to slow down memory loss.
 Ivosidenib Approved for Acute Myeloid Leukemia & Advanced Cholangiocarcinoma
Some people with an aggressive blood cancer called acute myeloid leukemia (AML) may soon have a new drug option called Ivosidenib that blocks the activity of IDH1 gene.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

Gluten-Free Pills: FDA Issues Guidance For Labeling Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests